The Pig-a assay is an emerging and promising in vivo method to determine mutagenic potential of chemicals. Since its development in 2008, remarkable progress has been made in harmonizing and characterizing the test procedures, primarily using known mutagenic chemicals. The purpose of the present study was to evaluate specificity of the Piga assay using two nongenotoxic and wellcharacterized rodent liver carcinogens, phenobarbital and clofibrate, in male F344/DuCrl rats. Daily oral administration of phenobarbital or clofibrate at established hepatotoxic doses for 28 days resulted in substantial hepatic alterations, however, did not increase the frequency of Pig-a mutation markers (RET CD59-and RBC CD59-) compared to vehicle control or pre-exposure (Day −5) mutant frequencies. These results are consistent with the existing literature on the nonmutagenic mode of action (MoA) of phenobarbital and clofibrate liver tumors. The present study contributes to the limited, but expanding evidence on the specificity of the Pig-a assay and further for the investigations of carcinogenic MoAs, i.e., mutagenic or nonmutagenic potential of chemicals. Environ. Mol. Mutagen. 60:42-46, 2019.
INTRODUCTION
The Pig-a assay was first developed in rodent models to evaluate the mutagenic potential of chemicals Miura et al., 2008a; 2008b; Phonethepswath et al., 2008) . The assay measures mutations in the Pig-a (phosphatidylinositol glycan, class A) gene by quantifying phenotypic variants for cell surface glycosylphosphatidylinositol (GPI)-anchored proteins (e.g. CD59 in rats). The Pig-a gene (an X-linked gene; single functional copy) codes for the catalytic subunit of N-acetyl glucosamine transferase, which is involved in GPI biosynthesis. In eukaryotes, GPI anchors a number of cell surface markers, including CD59, CD24, and CD55. A single inactivating mutation in the Pig-a gene is sufficient to make a cell deficient in GPI biosynthesis and thus is deficient in surface-bound GPI-anchored protein markers. In this assay, Pig-a mutant frequency is determined by incubating peripheral blood samples with fluorescent antibodies for GPI-anchored protein, which makes the wild-type cells fluoresce, while the mutant cells are devoid of fluorescence.
The assay gained immediate attention because of the ease to integrate with other repeat-dose toxicity endpoints, requirement of smaller amounts (~100 μL of blood) of sample, high-throughput analysis (flow cytometry based), and the relative ease to conduct (two-color panel). The GPI-biosynthesis pathway is highly conserved in most mammalian species; thus, the Pig-a assay has been evaluated in a number of mammalian species across many laboratories. As the method requires single-cell suspensions (for flow cytometric analysis) and expression of cellsurface markers, the Pig-a assay is most readily applied to peripheral blood cells. The procedure for this method has been refined in a series of formal and informal workshops consisting of experts from academic, regulatory, and industrial laboratories. Several multilaboratory and international initiatives have contributed to establishing best practices, demonstrating interlaboratory reproducibility, and expanding the chemical space to agents with a wide range of mutagenic potency.
A recently held International Workshop on Genotoxicity Testing (IWGT) suggested implementing the Pig-a assay as a follow-up to positive results in the bacterial and in vitro mammalian cell gene mutation assays (Gollapudi et al., 2015) . The assay has received extensive regulatory interest as a potential in vivo gene mutation assay (Dobrovolsky et al., 2010; Lynch et al., 2011b; Schuler et al., 2011; Godin-Ethier et al., 2015; Gollapudi et al., 2015) , including the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH-M7), and the process for development of an Organization for Economic Cooperation and Development (OECD) test guideline has been initiated. Therefore, applications of the Pig-a assay in regulatory chemical safety assessment are expected in the near future, especially in an animal saving and integrative manner.
To date, the Pig-a assay has been evaluated predominantly with a variety of genotoxic chemicals, and the assay correctly identified mutagenic potential of these chemicals. Therefore, the IWGT recommended to extend the evaluation of the Pig-a assay to chemicals that are anticipated to be negative for mutagenic potential. Such an assessment is critical to demonstrate the specificity of the Pig-a assay and the feasibility of utilizing this assay in carcinogenic Mode of Action (MoA) investigations.
Phenobarbital (PB), a widely used sedative, hypnotic, and anti-epileptic drug is an established rodent liver carcinogen (IARC, 2001) . Hepatocellular adenomas and carcinomas were consistently observed in its carcinogenicity studies with mice (IARC, 2001) ; however, the rat appears to be more resistant to hepatocarcinogenesis induced by PB treatment (reviewed in Elcombe et al., 2014) . Regardless, it is well accepted that PB is nongenotoxic (IARC, 2001) and activates the constitutive androstane receptor (CAR) in rats, mice, and humans (Elcombe et al., 2014) , although its carcinogenic MoA is not relevant to humans (Elcombe et al., 2014) . Clofibrate (CF), a pharmaceutical drug used for lowering cholesterol and triacylglyceride levels in the blood is also a rodent liver carcinogen (IARC, 1996) . The hepatocarcinogenic MoA has been established as a nongenotoxic peroxisome proliferator activated receptor-α (PPAR-α) activator in rodents and is not relevant to humans due to qualitative differences in the biological response between species (ARC, 1996; Boerrigter, 2004; Corton et al., 2014) . In a recent study, CF was found to be positive in a liver micronucleus assay, however, negative in bone marrow (Takayanagi et al., 2015) . This increase may be related to the mitogenic activity of CF in the rodent liver increasing background micronucleus formation and not necessarily genotoxicity per se.
In the present study, the performance of the Pig-a assay was evaluated using these two well-characterized experimental nongenotoxic rodent hepatocarcinogens, PB and CF.
MATERIALS AND METHODS

Animals, Chemicals, and Treatment
Seven-week-old male F344/DuCrl rats were purchased from Charles River Laboratories. (Kingston, NY). This strain was selected as it is commonly used in repeat-dose toxicology studies and toxicological effects of CF and PB have been evaluated previously in this strain. In the present study, rats were randomized based on body weight, identified using subcutaneously implanted transponders, housed one rat per cage in stainless steel cages and provided LabDiet Certified Rodent Diet (PMI Nutrition International, St. Louis, MO), and water ad libitum. Phenobarbital (PB; CAS # 50-06-6) was purchased from Sigma-Aldrich (Catalog No. P1636, lot No. SLBD2447V, purity 100%, St. Louis, MO). Clofibrate (CF; CAS # 637-07-0) was purchased from Alfa Aesar (Catalog No. J60342, lot No. F27X099, purity 98.8%, Ward Hill, MA). Methocel (0.5%) and corn oil were used as the solvent vehicle for PB and CF, respectively. Following seven-day acclimatization, rats were randomly assigned to treatment groups based on body weight (i.e., approximately equal mean body weights and variances across groups), and administered respective solvent vehicle or PB or CF by oral gavage at dose levels of 100 mg/kg/day (PB) or 300 mg/kg/day (CF) for 28 days (n = 5 rats/dose) (based on weekly body weights). The selected doses were identified to be the lowest carcinogenic doses in prior studies (Miousse et al., 2017) . All animal studies were conducted at The Dow Chemical Company, Toxicology and Environmental Research & Consulting (TERC), Midland, MI, which is accredited by the American Association for Accreditation of Laboratory Animal Care. All animal care and use activities were reviewed and approved by the Institutional Animal Care and Use Committee.
During the treatment period, a cage-side examination was conducted on all animals at least once a day. This examination was intended to monitor general health of the animals and to detect obvious clinical abnormalities, which included, decreased/increased activity, repetitive behavior, vocalization, incoordination/limping, injury, neuromuscular function (convulsion, fasciculation, tremor, and twitches), altered respiration, blue/pale skin and mucous membranes, severe eye injury (rupture), alterations in fecal consistency, and fecal/urinary quantity or color. In addition, all animals were observed for morbidity, mortality, and the availability of feed and water at least twice daily. Body weights of all rats were analyzed prior to exposure period, during the exposure period (weekly) and at the end of study. Body weight gains were calculated relative to study day 1 (first day of dosing). At the end of the study (24 h after last exposure), animals were anesthetized using a mixture of isoflurane vapors and medical oxygen (in a small inhalation chamber) and humanely euthanized. Major internal organs (liver, kidney, testis, and epididymis) were collected, weighed, and stored under appropriate conditions for subsequent analysis. Relative liver weights were determined by correcting absolute organ weights to respective terminal body weight (Table I) .
Pig-a Assay
Five days prior to the first dose (day −5), tail vein blood was collected from PB and CF rats to determine background Pig-a mutant frequency. This prescreening procedure was one of the recommendations by the IWGT to identify and eliminate potential biological outliers and to improve the sensitivity of the Pig-a assay (Gollapudi et al., 2015) . On study day 29, animals were euthanized and blood was collected via the orbital sinus from all animals. Blood was collected into K 2 EDTA tubes (Becton, Dickinson and Company, cat# 365973) and stored at 2-8 C for no more than 24 h prior to analysis. The Pig-a assay was conducted using the MutaFlowPLUS Kit (Litron Laboratories, cat# MutaFlow PLUS-25R, Rochester, NY), which adopts a mutant enrichment step based on immunomagnetic column seperation to increase the sensitivity of this assay by evaluating an enriched cell population of generally more than 3 × 10 6 reticulocytes (RETs) and 100 × 10 6 erythrocytes (RBCs) . In brief, 80 μL of blood sample was mixed with 100 μL of anticoagulant solution. The leukocytes were depleted with Lympholyte-Mammal 
Statistical Analyses
Endpoints were tested for equality of variance using Bartlett's test (alpha = 0.01). Based on the outcome of the Bartlett's test, no variables were transformed. The data were analyzed by a pairwise comparison (Student's t-test) of PB-or CF-treated groups versus respective control with a significance level of 0.05 using SAS/STAT software (version 9.2 SAS Institute, Cary, NC).
Pig-a Assay Interpretation Criteria
The IWGT-suggested interpretation criteria for classifying Pig-a responses are similar to those currently recommended for other genotoxicity assays (e.g., OECD TG 488), where both biological and statistical responses are considered to determine relevance of an observed (chemicalmediated) increase in mutant frequencies. Per the IWGT recommendation, a chemical is considered positive when it induces a significant and dosedependent increase in mutant frequency above the historical negative control values (Gollapudi et al., 2015) . A chemical is considered negative in the Pig-a mutation assay when the above criteria are not met. In the present study, rats were treated with PB or CF at a defined carcinogenic dose and changes in mutant frequencies were compared to respective controls and pre-exposure values (Table II) .
RESULTS AND DISCUSSION
Clinical Observations, General Toxicity, and Target Organ Effects
No remarkable clinical signs were observed in any animal during the study period. As shown in Table I , on study day 28, the body weight gain in the PB group was significantly higher than that in the vehicle control group, presumably due to an increase in liver weight. As expected, the absolute and relative liver weights (g/100) were significantly increased in the PB group. The body weight gain in the CF group was slightly higher, though the increase was not statistically different compared to the vehicle control group. As expected, the liver weight and relative liver weight (g/100) in the CF group were significantly increased compared to the vehicle control group. In the present study, PB and CF treatment resulted in an increase in relative liver weight of 61% and 116%, respectively, which exceeds the criteria established for a maximum tolerated dose (MTD) as defined by numerous regulatory agencies for an adverse response in a repeat-dose study (WHO, 2015) . These observations are consistent with previous publications, which suggested similar increases in relative liver weights, hepatomegaly, and hepatocellular hypertrophy following PB and CF exposures (Corton et al., 2014; Elcombe et al., 2014; Miousse et al., 2017) . Following oral administration, both PB and CF are rapidly absorbed and transported via the blood, consistent with their pharmaceutical applications (Cayen et al., 1977; Geter et al., 2014) . Furthermore, a recent publication has evaluated the in vivo mutagenic response of genotoxic chemicals in a 28-day dosing paradigm at fractions of the carcinogenic dose (Dertinger et al., 2014) . The authors demonstrated a Pig-a mutagenic response at doses far below a traditional MTD, providing clear indications of assay sensitivity and applicability for a mechanistic and quantitative carcinogenic assessment.
Pig-a Assay
Although no concurrent positive control was included in this study, we have previously demonstrated proficiency in the Pig-a assay (Ji et al., 2015) . Comparison of the preand post-exposure data of the %RET values indicated a substantial decrease in the F344 rats utilized in this study. This was consistent with the reports in Sprague Dawley rats from other laboratories (Cammerer et al., 2011; Dertinger et al., 2011b; Lynch et al., 2011a; Stankowski et al., 2011; Kimoto et al., 2012; Torous et al., 2012; Gunther et al., 2014) , indicating that this is a biological aging phenomenon.
To evaluate biological relevance of a negative result, the IWGT-suggested assessing the treatment-related decrease in percent reticulocytes in peripheral blood as a biomarker of bone marrow exposure to the test agent or its metabolite. In the present study, after 28-day exposure to PB, % RET was slightly but significantly increased compared to the vehicle controls, suggesting bone marrow exposure to the test material or metabolites (Table II) . A similar increase in %RET was also observed in CF-treated group, however, the difference did not reach statistical significance.
The frequencies of RET CD59-and RBC CD59-in the vehicle control animals and PB-or CF-treated animals were all within the reported background range of 0-5 × 10 −6 (Gollapudi et al., 2015) . Between test day −5 (pre-exposure) and test day 29, there were no significant increases in frequencies of RET CD59-and RBC CD59-in the PB-treated, or CF-treated rats compared to their respective vehicletreated (control) animals (Table II) . Taken together, these results suggested that PB or CF did not induce Pig-a gene mutations following 28 days of exposure at selected dose levels in rodents. These results are consistent with the previously established lack of in vivo genotoxicity for PB and CF in rodents (summarized in Corton et al., 2014; Elcombe et al., 2014) .
CONCLUSIONS AND FUTURE DIRECTIONS
In the present study, two well-characterized nongenotoxic rodent carcinogens, PB and CF, were tested in the Pig-a assay at carcinogenic dose levels. The negative Pig-a results confirmed nonmutagenic potential of these chemicals, consistent with the existing literature. This study could contribute to the ongoing Organization for Economic Cooperation and Development (OECD) test guideline development for the Pig-a assay. Guidance provided by the OECD indicates that assay validation should include a demonstration that the assay measures what it is designed to measure. Prior studies demonstrated sensitivity of the Pig-a assay to identify chemicals with the mutagenic potential. The present study contributes to the limited, but expanding evidence on the specificity of the assay. In addition, the present study suggests high potential of the Pig-a assay to investigate carcinogenic MoAs, i.e., mutagenic or nonmutagenic potential of chemicals.
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